Two leading entities in cancer research pledge scientific collaboration to advance precision oncology.HAMBURG, Germany and ROCHESTER, N.Y., Dec. 10, 2025…
– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement –– Strong activity observed…
December 06, 2025 17:30 ET | Source: TScan Therapeutics, Inc. Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23)…
December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear dose-response observed, with a robust and clinically meaningful…
Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026Topline results from…
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company specializing in developing transformative treatments for rare diseases,…
November 28, 2025 20:13 ET | Source: Rakovina Therapeutics Inc VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Rakovina…
November 28, 2025 08:00 ET | Source: Spero Therapeutics, Inc. CAMBRIDGE, Mass., Nov. 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics,…
BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on…
November 18, 2025 16:30 ET | Source: Protara Therapeutics NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.…